| Dr John A Albert, MD | |
|
7080 N Port Washington Rd, Glendale, WI 53217-3838 | |
| (414) 351-4009 | |
| (414) 351-4009 |
| Full Name | Dr John A Albert |
|---|---|
| Gender | Male |
| Speciality | Rheumatology |
| Experience | 33 Years |
| Location | 7080 N Port Washington Rd, Glendale, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1861428070 | NPI | - | NPPES |
| 32466600 | Medicaid | WI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RR0500X | Internal Medicine - Rheumatology | 39779 (Wisconsin) | Primary |
| 207P00000X | Emergency Medicine | 39779 (Wisconsin) | Secondary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Rheumatic Disease Center | 0840210852 | 11 |
News Archive
Kaiser Health News staff writer Julie Appleby reports: "Regulators are set to vote Thursday on controversial rules governing how much insurers must spend on patients' medical care - a key provision of the new health overhaul law" (Appleby, 10/20).
The researchers are the first to identify a population of cells with characteristics of adult and embryonic stem cells in cultures derived from biopsies of patients' bone tumors. They describe their findings in the medical journal Neoplasia.
A new study suggests that middle-aged adults recently diagnosed with diabetes and hypertension have time to try to learn how to control their high blood pressure without medications, but not too much time.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 1 days ago
| Entity Name | Rheumatic Disease Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609812544 PECOS PAC ID: 0840210852 Enrollment ID: O20051205000691 |
News Archive
Kaiser Health News staff writer Julie Appleby reports: "Regulators are set to vote Thursday on controversial rules governing how much insurers must spend on patients' medical care - a key provision of the new health overhaul law" (Appleby, 10/20).
The researchers are the first to identify a population of cells with characteristics of adult and embryonic stem cells in cultures derived from biopsies of patients' bone tumors. They describe their findings in the medical journal Neoplasia.
A new study suggests that middle-aged adults recently diagnosed with diabetes and hypertension have time to try to learn how to control their high blood pressure without medications, but not too much time.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr John A Albert, MD 7080 N Port Washington Rd, Glendale, WI 53217-3838 Ph: (414) 351-4009 | Dr John A Albert, MD 7080 N Port Washington Rd, Glendale, WI 53217-3838 Ph: (414) 351-4009 |
News Archive
Kaiser Health News staff writer Julie Appleby reports: "Regulators are set to vote Thursday on controversial rules governing how much insurers must spend on patients' medical care - a key provision of the new health overhaul law" (Appleby, 10/20).
The researchers are the first to identify a population of cells with characteristics of adult and embryonic stem cells in cultures derived from biopsies of patients' bone tumors. They describe their findings in the medical journal Neoplasia.
A new study suggests that middle-aged adults recently diagnosed with diabetes and hypertension have time to try to learn how to control their high blood pressure without medications, but not too much time.
Relapsing-Remitting Multiple Sclerosis (RRMS) patients have been anticipating the availability of new oral therapies being developed to treat their specific condition. Among the string of oral therapies entering the market is Novartis' Gilenya, which recently became available for use following receipt of FDA approval in late September. One-third of MS patients are aware the new oral agents are under development and there is substantial interest within this group to seek further information through physicians and other sources, according to new research by GfK HealthCare.
HemaQuest Pharmaceuticals announced today that it has initiated the Company's Phase 2 clinical trial evaluating its proprietary HQK-1004 therapy for the treatment of lymphomas and related cancers associated with Epstein-Barr virus (EBV) infection. These EBV-related cancers have poor prognoses and short patient survival. Currently available cancer therapies are typically much less effective in patients with EBV-related lymphoid malignancies than in patients who have similar cancers not infected with the virus.
› Verified 1 days ago
Talal R Khairi, MD Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5650 N Green Bay Ave Ste 210, Glendale, WI 53209 Phone: 414-431-5971 Fax: 414-434-0354 | |
Dr. Rishi Kora, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5650 N Green Bay Ave Ste 210, Glendale, WI 53209 Phone: 414-431-5971 Fax: 414-434-0354 | |
Dr. Jonathan Kushi, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 7080 N Port Washington Rd, Glendale, WI 53217 Phone: 414-351-4009 Fax: 414-351-7060 | |
Dr. Primo R Tamayo, M.D. Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 2501 W Silver Spring Dr, Glendale, WI 53209 Phone: 414-461-9250 Fax: 414-461-3553 | |
Dr. Stephen Glenn Sievers, M.D. Rheumatology Medicare: Medicare Enrolled Practice Location: 5650 N Green Bay Ave Ste 100, Glendale, WI 53209 Phone: 414-431-5971 Fax: 414-434-0354 | |
Dr. Lisa Haller, M.D. Rheumatology Medicare: Accepting Medicare Assignments Practice Location: 5650 N Green Bay Ave Ste 210, Glendale, WI 53209 Phone: 414-431-5971 Fax: 414-434-0354 | |
Dr. Stephen C. Hinkle, MD Rheumatology Medicare: Not Enrolled in Medicare Practice Location: 7080 N Port Washington Rd, Glendale, WI 53217 Phone: 414-351-4009 Fax: 414-351-7060 |